Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Lumacaftor Plus Ivacaftor Combination
Vertex Pharmaceuticals (Australia) Pty.
Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
1 trial -
Lurasidone
Sumitomo Pharma (Suzhou) Co.,
Bipolar I Depression
1 trial -
Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets
The George Institute
Patients with a histological diagnosis of p53abn HREC, treated with curative intent, after surgery (hysterectomy and bilateral salpingooophorectomy, with or without lymphadenectomy or sentinel node biopsy), without signs of residual disease or distant metastases
1 trial -
Lynparza 100 mg film-coated tablets, Sodium Chloride Intravenous Infusion BP 0.9% w/v Solution for Infusion (not authorised), Placebo film-coated tablet (Not Authorised), Lynparza 150 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, INFLIXIMAB, BEVACIZUMAB
AstraZeneca AB
Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian or primary peritoneal cancer
1 trial -
MB-102 DMID
Hangzhou Zhongmei Huadong Pharmaceutical Co.,
Kidney Diseases
1 trial -
MCV-ACYW135 Vaccine Group
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Meningitis
1 trial -
MEDI4736
AstraZeneca
Squamous Cell Carcinoma of the Head and Neck
1 trial -
METHOTREXATE, LENALIDOMIDE, LENALIDOMIDE
Pari Pharma GmbH
Cutaneous lupus erythematosus
1 trial -
METYRAPONE ESTEVE 250 mg, capsule molle, Placebo of metyrapon 250 mg
Pari Pharma GmbH
Primary Bilateral Macronodular Adrenal Hyperplasia causing moderate Cushing Syndrome (Mild autonomous Cortisol secretion)
1 trial -
MIDAZOLAM , CEDACONDA 100 % V/V, liquide pour inhalation par vapeur, PROPOFOL
Pari Pharma GmbH
Adult patients with severe cardiogenic shock on venoarterial ECMO support for less than 24 hours.
1 trial -
MIDAZOLAM, DEXMEDETOMIDINE EVER PHARMA 100 microgrammes/mL, solution à diluer pour perfusion
Pari Pharma GmbH
Very preterm neonate (gestational age at birth < 32 WG) with corrected gestational age <45 WG) with indication for sedation in the context of invasive mechanical ventilation
1 trial -
MITAPIVAT, MITAPIVAT, "Placebo to Match Mitapivat Tablets, 5 mg and 20 mg, are supplied as film-coated, blue, round tablets for oral administration Placebo to Match Mitapivat Tablets, 50 mg or 100 mg, are supplied as film-coated, blue, oblong tablets for oral administration. Placebo to Match Mitapivat Granules, 1 mg, are supplied as film-coated, white, round granules for oral administration", MITAPIVAT
Lacuna Pharma Pty Ltd
Anemia in subjects with sickle cell disease (SCD)
1 trial -
MK-0616, Placebo to MK-0616
Merck Sharp and Dohme
Heterozygous Familial Hypercholesterolemia in pediatric patients
1 trial -
MK-1022, CAPECITABINE , PACLITAXEL , TRASTUZUMAB DERUXTECAN , PACLITAXEL ALBUMIN-BOUND, DOXORUBICIN , DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL
Merck Sharp and Dohme
Hormone receptor positive breast cancer
1 trial -
MK-2870, GEMCITABINE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , -, PACLITAXEL ALBUMIN-BOUND, PACLITAXEL
Merck Sharp and Dohme
Locally recurrent unresectable or metastatic TNBC with tumors expressing PD-L1 at the cut-off of CPS <10
1 trial -
MK-2870, PACLITAXEL ALBUMIN-BOUND, -, PACLITAXEL , -, -, DOXORUBICIN , PARACETAMOL, COMBINATIONS EXCL. PSYCHOLEPTICS
Merck Sharp and Dohme
Endometrial cancer
1 trial -
MK-2870, PARACETAMOL , TOPOTECAN , -, TISOTUMAB VEDOTIN, IRINOTECAN , PEMETREXED , -, -, GEMCITABINE , MK-2870, VINORELBINE
Merck Sharp and Dohme
Recurrent or metastatic cervical cancer that has progressed on or after treatment with platinum-doublet systemic chemotherapy and anti-PD-L1/anti-PD-1 therapy.
1 trial -
MK-3475A, PEMETREXED , MK-1084, MK-1084, CISPLATIN , CARBOPLATIN , MK-1084, MK-1084
Merck Sharp and Dohme
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC
1 trial -
MORPHINE , PENTHROX 99,9%, liquide pour inhalation par vapeur de 3 mL
Pari Pharma GmbH
Acute Myocardial Infarction
1 trial -
MRTX1719, CARBOPLATIN, CISPLATIN, PEMETREXED, MRTX1719 Matching Placebo, PACLITAXEL ALBUMIN-BOUND, PEMBROLIZUMAB, PACLITAXEL
Bristol-Myers Squibb Australia Pty Ltd
metastatic non-small cell lung cancer
1 trial -
MYCOHYDRALIN 500 mg, capsule vaginale, FLAGYL 500 mg, comprimé pelliculé, ZITHROMAX 250 mg, comprimé pelliculé, ROCEPHINE 1 g/3,5 ml, poudre et solvant pour solution injectable (IM), GRANUDOXY 100 mg, comprimé pelliculé sécable
ISTA Pharma Limited
Bacterial vaginosis, High risk preterm birth pregnancy, Vaginal flora abnormalities
1 trial -
MYCOPHENOLATE MOFETIL, ETOPOSIDE, DURVALUMAB, INFLIXIMAB, SILTUXIMAB, Tarlatamab, CARBOPLATIN, Tarlatamab
Amgen
Extensive stage small cell lung cancer (ES-SCLC). Small-cell lung cancer, accounting for 10% to 15% of lung cancer (Rudin et al, 2015), is an aggressive lung cancer subtype with neuroendocrine differentiation and strongly associated with smoking (Koinis et al, 2016). It displays a distinct natural history characterized by a high growth fraction, rapid doubling time and early establishment of widespread metastatic lesions (Gustafsson et al, 2008). Around 70% of patients are diagnosed with ES-SCLC, presenting with distant metastasis or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan.
1 trial -
Maintenance Pembrolizumab at Usual or Low doSE in non-squamous lung cancer: a non-inferiority study
The George Institute
Maintenance treatment in metastatic non-squamous lung cancer
1 trial -
Matching placebo for BAY 597939 2.5 mg filmcoated tablets, Rivaroxaban 2.5 mg
The George Institute
Improvement of cardiovascular outcomes in patients with advanced chronic kidney disease. In easily understood language, this is Heart and blood vessel disease and Kidney disease.
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources